Literature DB >> 18947321

Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes.

Anucha Apisarnthanarak1, Pattarachai Kiratisin, Linda M Mundy.   

Abstract

OBJECTIVES: To characterize healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes, as opposed to a single ESBL gene.
METHODS: All patients with a confirmed healthcare-associated infection due to an ESBL-producing strain of E. coli or K. pneumoniae were enrolled in the study. Molecular typing of isolates was performed, and the comparative risks and outcomes of patients were analyzed.
RESULTS: Among 71 patients with healthcare-associated infection due to an ESBL-producing strain of E. coli or K. pneumoniae, the gene for CTX-M, with or without other ESBL genes, was identified in all 51 (100%) of the patients infected with an E. coli strain and in 18 (90%) of the 20 patients infected with a K. pneumoniae strain. Of these 71 patients, 17 (24%) met the definition of healthcare-associated infection due to an ESBL-producing strain that harbored multiple genes; in multivariate analysis, previous exposure to 3 or more classes of antibiotics (adjusted odds ratio, 4.5 [95% confidence interval, 1.7-75.2]) was the sole risk factor for healthcare-associated infection due to an ESBL-producing strain that harbored multiple ESBL genes. Isolates recovered from patients with healthcare-associated infection due to an ESBL-producing strain that harbored multiple ESBL genes were more resistant to various antibiotic classes, and, compared with patients with healthcare-associated infection due to an ESBL-producing strain that harbored a single ESBL gene, they were more likely to have ineffective initial empirical antimicrobial therapy (52% vs 94%; odds ratio, 5.1 [95% confidence interval, 1.04-14.5]).
CONCLUSIONS: CTX-M ESBL is highly prevalent in Thailand. Patients with healthcare-associated infection due to an ESBL-producing strain that harbored multiple ESBL genes were more likely to have had ineffective initial empirical antimicrobial therapy, and, given that antibiotic selection pressure was the only associated risk, we suggest focused antimicrobial stewardship programs to limit the emergence and spread of healthcare-associated infection due to ESBL-producing strains in this middle-income country.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18947321     DOI: 10.1086/591864

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Antimicrobial Susceptibility of Klebsiella pneumoniae and Escherichia coli with Extended-Spectrum β-lactamase associated Genes in Hospital Tengku Ampuan Afzan, Kuantan, Pahang.

Authors:  Saleh Mahdi Yahya Mohsen; Hairul Aini Hamzah; Mustafa Muhammad Imad Al-Deen; Roesnita Baharudin
Journal:  Malays J Med Sci       Date:  2016-03

2.  Phenotypic Tests for the Detection of β-Lactamase-Producing Enterobacteriaceae Isolated from Different Environments.

Authors:  Daniele V de Oliveira; Sueli T Van Der Sand
Journal:  Curr Microbiol       Date:  2016-04-12       Impact factor: 2.188

Review 3.  Escherichia coli Isolated from Urinary Tract Infections of Lebanese Patients between 2005 and 2012: Epidemiology and Profiles of Resistance.

Authors:  Ziad Daoud; Elie Salem Sokhn; Khalil Masri; Ghassan M Matar; Shira Doron
Journal:  Front Med (Lausanne)       Date:  2015-04-30

Review 4.  Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses.

Authors:  Tirza C Hendrik; Anne F Voor In 't Holt; Margreet C Vos
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

5.  Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia.

Authors:  Nuntra Suwantarat; Karen C Carroll
Journal:  Antimicrob Resist Infect Control       Date:  2016-05-04       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.